| Treatment Outcomes in Patients with Advanced Fibrolamellar Hepatocellular Carcinoma Under Systemic Treatment: Analysis of Clinical Characteristics, Management, and Radiomics LG Da Fonseca, VJ Yamamoto, M Trinconi Cunha, GS Torre, RLC Araujo, ... Journal of Hepatocellular Carcinoma, 1923-1933, 2023 | | 2023 |
| Liver decompensation is a frequent cause of treatment discontinuation and prognostic factor in intermediate-advanced HCC F Piñero, M Anders, C Bermudez, E Demirdjian, A Varón, A Palazzo, ... Annals of Hepatology 28 (4), 101110, 2023 | 4 | 2023 |
| Brazilian Society of Hepatology Updated Recommendations for Systemic Treatment of Hepatocellular Carcinoma AL Chagas, CRG Leal, VB Mello, FMDR Barros, PL Bittencourt, AA Mattos, ... Arquivos de gastroenterologia 60, 106-131, 2023 | | 2023 |
| Early variation of inflammatory indexes refines prognostic prediction in patients with hepatocellular carcinoma under systemic treatment LG Da Fonseca, LF Uratani, GF Soares, PS Do Amaral, ... Molecular and clinical oncology 18 (4), 1-8, 2023 | 1 | 2023 |
| P-10 PATTERNS OF PROGRESSION AND TREATMENT DISCONTINUATION IN A REAL LIFE LATIN AMERICAN PROSPECTIVE COHORT STUDY OF INTERMEDIATE-ADVANCED HEPATOCELLULAR CARCINOMA: SECOND … F Piñero, M Anders, C Bermudez, E Demirdjian, A Varón, A Palazzo, ... Annals of Hepatology 28, 100914, 2023 | | 2023 |
| Atualização das Recomendações da Sociedade Brasileira de Hepatologia para o Tratamento Sistêmico do Carcinoma Hepatocelular AL CHAGAS, CRG LEAL, VB MELLO, FMDR BARROS, ... Arq. gastroenterol, 106-131, 2023 | 1 | 2023 |
| Hepatocellular carcinoma (HCC) in patients with Non-Alcoholic Fatty Liver Disease (NAFLD): screening, treatment and survival analysis in a Brazilian series RSSM Alencar, CP Oliveira, AL Chagas, LG Fonseca, C Maccali, ... Clinics 77, 100097, 2022 | 1 | 2022 |
| Immunotherapy-Based Treatments of Hepatocellular Carcinoma: AJR Expert Panel Narrative Review R Cannella, S Lewis, L da Fonseca, M Ronot, J Rimola American Journal of Roentgenology 219 (4), 533-546, 2022 | 9 | 2022 |
| Outcome of liver cancer patients with SARS‐CoV‐2 infection: an international, multicentre, cohort study S Muñoz‐Martínez, V Sapena, A Forner, J Bruix, M Sanduzzi‐Zamparelli, ... Liver international 42 (8), 1891-1901, 2022 | 13 | 2022 |
| Low Baseline Plasma L-Glutamine Concentration Identifies Hepatocellular Carcinoma Patients at High Risk of Developing Early Gastrointestinal Adverse Events during Sorafenib … L Boix, V Sapena, E Samper, Á Díaz-González, N Llarch, G Iserte, ... Gastrointestinal Disorders 4 (3), 141-152, 2022 | | 2022 |
| Association between metabolic disorders and cholangiocarcinoma: impact of a postulated risk factor with rising incidence LG Da Fonseca, PH Hashizume, IS de Oliveira, L Izquierdo-Sanchez, ... Cancers 14 (14), 3483, 2022 | 2 | 2022 |
| Combination approaches in hepatocellular carcinoma: how systemic treatment can benefit candidates to locoregional modalities LG da Fonseca, RLC Araujo World Journal of Gastroenterology 28 (28), 3573, 2022 | 5 | 2022 |
| Irinotecan combined with Panitumumab or cetuximab as third-line treatment for metastatic colorectal cancer. MI Braghiroli, MFB Vicentini, LG Fonseca, KT Souza, RC Bonadio, ... Journal of Clinical Oncology 40 (16_suppl), e15551-e15551, 2022 | | 2022 |
| A multidisciplinary approach to peritoneal metastasis from hepatocellular carcinoma: clinical features, management and outcomes L Da Fonseca, P Leonardi, P Hashizume, F Sansone, L Saud, F Carrilho, ... Clinical and experimental hepatology 8 (1), 42-48, 2022 | 4 | 2022 |
| The complexity of cholangiocarcinoma goes beyond clinical practice: Challenges in trials design and interpretation. LG Da Fonseca, A Forner Liver International 42 (2), 2022 | | 2022 |
| Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study M de la Torre-Aláez, A Matilla, M Varela, M Iñarrairaegui, M Reig, ... Journal for immunotherapy of cancer 10 (11), 2022 | 30 | 2022 |
| Methylene tetrahydrofolate reductase (MTHFR) and vascular endothelial growth factor (VEGF) polymorphisms in Brazilian patients with Hepatitis C virus (HCV)-related … SCR Carvalho, LRS Vasconcelos, L Fonseca, RF Carmo, MT Tomitão, ... Clinics 76, e2881, 2021 | 5 | 2021 |
| aspirin and NSAID for chemoprevention of hepatocellular carcinoma—ready for their use? LG Da Fonseca, A Forner Alimentary Pharmacology & Therapeutics 54 (6), 2021 | 5 | 2021 |
| P-10 Latin american registry of cholangiocarcinoma: Clinical features, management and outcomes LG da Fonseca, L Izquierdo-Sanchez, PH Hashizume, EL Beca, Y Carlino, ... Annals of Hepatology 24, 100376, 2021 | 1 | 2021 |
| Early diarrhoea under sorafenib as a marker to consider the early migration to second‐line drugs Á Díaz‐González, V Sapena, L Boix, F Torres, M Sanduzzi‐Zamparelli, ... UEG Journal 9 (6), 655-661, 2021 | 1 | 2021 |
